| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/22/2009 | EP2079441A1 Topical antibiotic composition for the prevention of lyme disease |
| 07/22/2009 | EP2079440A2 Two-compartment skincare products comprising ivermectin, and uses thereof |
| 07/22/2009 | EP2079439A1 Methods and ophthalmic devices used in the treatment of ocular allergies |
| 07/22/2009 | EP2079389A2 Resorbable pouches for implantable medical devices |
| 07/22/2009 | EP2079324A2 Novel composition and uses thereof, in particular cosmetic uses, for treating skin dehydration |
| 07/22/2009 | EP2079320A2 Antioxidant dietary supplement compositions and methods for maintaining healthy skin |
| 07/22/2009 | EP2079313A2 Antimicrobial and antiviral compounds and methods for their use |
| 07/22/2009 | EP2079309A1 Smac mimetic dimers and trimers useful as anti-cancer agents |
| 07/22/2009 | EP2079307A2 Farnesoid x receptor agonists |
| 07/22/2009 | EP2079306A2 Mucosally non-irritative amphotericin b formulations and methods for treating non-invasive fungus-induced mucositis |
| 07/22/2009 | EP2079304A1 Amine base salts of saha and polymorphs thereof |
| 07/22/2009 | EP2079301A1 Improved tissue maintenance |
| 07/22/2009 | EP2012768A4 Oral patch with salt of glycyrrhetinic acid water soluble at human mouth temperatures |
| 07/22/2009 | EP2007731B1 Process for the preparation of caprolactam cgrp antagonist intermediate |
| 07/22/2009 | EP2006377A9 Novel tumor antigen peptides |
| 07/22/2009 | EP2006286A9 Isoxazole derivative and isothiazole derivative having inhibitory activity on 11 beta -hydroxysteroid dehydrogenase type i |
| 07/22/2009 | EP2005968A9 Nanocomposite particle |
| 07/22/2009 | EP1998784B1 Medicaments and methods comprising a compound that promotes oestrogenic activity for wound healing |
| 07/22/2009 | EP1991692A4 Method and reagents for treating hepatic fibrosis and inflammation |
| 07/22/2009 | EP1989192B1 1,3-dioxane carboxylic acids |
| 07/22/2009 | EP1928858B1 Solid salt forms of a pyrrole substituted 2-indolinone |
| 07/22/2009 | EP1896460B1 Benzofuranyl derivatives as 5-ht6-receptor inhibitors |
| 07/22/2009 | EP1890692B1 Formulations of lipoic acid and the benzyl ester of hyaluronic acid in the pharmaceutical and cosmetic fields |
| 07/22/2009 | EP1877052B1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 07/22/2009 | EP1828166B1 Hydantoin derivatives useful as metalloproteinase inhibitors |
| 07/22/2009 | EP1750704B1 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| 07/22/2009 | EP1745039A4 3-aryl-5,6-disubstituted pyridazines |
| 07/22/2009 | EP1729753B1 Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity |
| 07/22/2009 | EP1727540A4 Melanin-concentrating hormone receptor antagonists and methods of use |
| 07/22/2009 | EP1678169B1 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer |
| 07/22/2009 | EP1667996B1 Quinazoline derivatives |
| 07/22/2009 | EP1667964B1 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 07/22/2009 | EP1663395B1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 07/22/2009 | EP1648452B1 2-imino-4-(thio)oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors |
| 07/22/2009 | EP1646610B1 Tetrahydrocarbazole derivatives and their pharmaceutical use |
| 07/22/2009 | EP1644337B1 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 07/22/2009 | EP1625112B1 Novel compounds for treatment of obesity |
| 07/22/2009 | EP1623714A4 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases |
| 07/22/2009 | EP1616184B1 A method and kit for detecting the early onset of renal tubular cell injury |
| 07/22/2009 | EP1594498B1 Use of etazolate for the treatment of degenerative ocular pathologies |
| 07/22/2009 | EP1569628B1 Novel use of lycopene for the treatment of diseases associated with androgen signalling |
| 07/22/2009 | EP1567524B1 Thia-epothilone derivatives for the treatment of cancer |
| 07/22/2009 | EP1563099B1 Induction of the mitochondrial permeability transition |
| 07/22/2009 | EP1542981B1 Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles from cyclohexanes and cyclohexanones as intermediates |
| 07/22/2009 | EP1517684B1 Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
| 07/22/2009 | EP1503988B1 Fredericamycin derivatives |
| 07/22/2009 | EP1499290B1 Warming and nonirritating lubricant compositions |
| 07/22/2009 | EP1492761B1 Amino acids with affinity for the alpha-2-delta-protein |
| 07/22/2009 | EP1474390B1 Indole derivatives substituted with long-chain alcohols and medicaments containing them |
| 07/22/2009 | EP1458413B1 Pharmaceutical compositions based on azetidine derivatives |
| 07/22/2009 | EP1453528B1 Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders |
| 07/22/2009 | EP1392680B1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
| 07/22/2009 | EP1392337B2 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating |
| 07/22/2009 | EP1392241B1 System for osmotic delivery of pharmaceutically active agents |
| 07/22/2009 | EP1391456B1 2-iminoimidazole derivatives |
| 07/22/2009 | EP1358159B1 3,4-diaminopyridine tartrate and phosphate, pharmaceutical compositions and uses thereof |
| 07/22/2009 | EP1299354B1 Factor viia inhibitory (thio)urea derivatives, their preparation and their use |
| 07/22/2009 | EP1282447B1 Stable polymeric micelle-type drug composition and method for the preparation thereof |
| 07/22/2009 | EP1263719B1 N-deacetylthiocolchine derivatives and pharmaceutical compositions containing them |
| 07/22/2009 | EP1255563B1 Composition of antigen and glycolipid adjuvant sublingual administration |
| 07/22/2009 | EP1244455B1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 07/22/2009 | EP1220689B1 Medicament for the treatment of chronic fatigue syndrome associated with fibromyalgia and irritable bowel syndrome. |
| 07/22/2009 | EP1131461B1 Use of hydroxamate compounds for the treatment of HER-2/neu-positive carcinomas |
| 07/22/2009 | EP1115390B1 Hydroxamate-containing cysteine and serine protease inhibitors |
| 07/22/2009 | EP1093381B2 Antigenic peptides derived from telomerase |
| 07/22/2009 | EP1027033B1 High efficiency encapsulation of nucleic acids in lipid vesicles |
| 07/22/2009 | CN101489568A Condensation products, method for their production and use thereof in medicaments, as disinfectants or as a tannin |
| 07/22/2009 | CN101489567A Mixtures of tannins, their production and use in medicaments or as disinfectants |
| 07/22/2009 | CN101489566A Rnai modulation of aha and therapeutic uses thereof |
| 07/22/2009 | CN101489565A Compounds and methods for modulating expression of gccr |
| 07/22/2009 | CN101489564A Antiviral phosphinate compounds |
| 07/22/2009 | CN101489563A Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations |
| 07/22/2009 | CN101489562A JAK inhibitors for treatment of myeloproliferative disorders |
| 07/22/2009 | CN101489561A Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders |
| 07/22/2009 | CN101489560A Controlled released preparations of oxcarbazepine having sigmoidal release profile |
| 07/22/2009 | CN101489559A Purine and deazapurine derivatives as pharmaceutical compounds |
| 07/22/2009 | CN101489558A Acetylenic heteroaryl compounds |
| 07/22/2009 | CN101489557A Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same |
| 07/22/2009 | CN101489556A Glucocorticoid receptor modulator and methods of use |
| 07/22/2009 | CN101489555A Nf-kappa |
| 07/22/2009 | CN101489554A Deoxynojirimycin and d-arabinitol analogs and methods of using |
| 07/22/2009 | CN101489553A Combinations of monoamine reuptake inhibitors and potassium channel activators |
| 07/22/2009 | CN101489552A Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders |
| 07/22/2009 | CN101489551A Aminoindazole urea derivatives |
| 07/22/2009 | CN101489550A Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane -3-carboxylic acid derivatives |
| 07/22/2009 | CN101489549A New indications for direct thrombin inhibitors in the cardiovascular field |
| 07/22/2009 | CN101489548A Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
| 07/22/2009 | CN101489547A Macrocyclic kinase inhibitors |
| 07/22/2009 | CN101489546A Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
| 07/22/2009 | CN101489545A Composition for foodstuff for binding acetaldehyde |
| 07/22/2009 | CN101489544A Methods for treating blood disorders |
| 07/22/2009 | CN101489542A Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases |
| 07/22/2009 | CN101489541A Use of polyamines in the treatment of psoriasis |
| 07/22/2009 | CN101489540A Ruthenium II compounds |
| 07/22/2009 | CN101486756A Outer surface proteins, their genes, and their use |
| 07/22/2009 | CN101486682A N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 07/22/2009 | CN101486679A 5HT2c receptor modulators |
| 07/22/2009 | CN101486678A 5HT2C receptor modulators |
| 07/22/2009 | CN101486677A 5HT2c receptor modulators |
| 07/22/2009 | CN101485679A Medicament for preventing and treating hyperlipemia |